The SELECT Trial: Semaglutide's 20% Cardiovascular Benefit
Released · Last reviewed
The SELECT trial showed semaglutide 2.4mg cut major adverse cardiovascular events by about 20% in adults with overweight or obesity and established cardiovascular disease, but without diabetes — a landmark result beyond weight loss.
- SELECT enrolled ~17,600 adults with CVD and overweight/obesity, no diabetes.
- Semaglutide 2.4mg reduced major cardiac events ~20% vs placebo.
- The benefit applies to the FDA-approved product, not compounded formulations.
- Results support semaglutide as cardiovascular therapy, not only weight loss.
What SELECT tested
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a large randomized trial of about 17,600 adults aged 45 and older who had established cardiovascular disease and overweight or obesity, but did not have diabetes.
Participants received either semaglutide 2.4mg weekly — the same dose approved as Wegovy for weight management — or placebo, and were followed for major adverse cardiovascular events: cardiovascular death, non-fatal heart attack, or non-fatal stroke.
The trial was designed to answer whether semaglutide's benefits extend beyond weight loss to hard cardiovascular outcomes, a question with large implications for how the drug is used and covered.
The results
Semaglutide reduced the risk of major adverse cardiovascular events by approximately 20% compared with placebo. This was a statistically significant and clinically meaningful reduction in the kind of outcomes — heart attacks, strokes, cardiovascular deaths — that matter most.
Importantly, the benefit appeared to be only partly explained by weight loss, suggesting semaglutide has cardiovascular effects beyond its effect on body weight. The result led to an expanded FDA indication for cardiovascular risk reduction.
It is worth distinguishing relative from absolute risk: a 20% relative reduction translates to a smaller absolute difference, but across a high-risk population the number of events prevented is substantial.
| Element | Detail |
|---|---|
| Population | ~17,600 adults, CVD + overweight/obesity, no diabetes |
| Intervention | Semaglutide 2.4mg weekly vs placebo |
| Primary outcome | Major adverse cardiovascular events |
| Result | ~20% relative risk reduction |
Who the result applies to
SELECT enrolled a specific population: adults with established cardiovascular disease and overweight or obesity, without diabetes. The 20% benefit is most directly applicable to people who resemble that group.
It does not automatically apply to everyone taking semaglutide for weight loss, and it says nothing about compounded semaglutide, which was not studied. The evidence is for the FDA-approved 2.4mg product.
For a person with cardiovascular disease considering semaglutide, SELECT is a strong reason to discuss the approved product with a clinician rather than a compounded alternative.
Why this matters for compounded products
SELECT tested the FDA-approved semaglutide product manufactured to a defined standard. Compounded semaglutide is a different, non-FDA-approved product with no cardiovascular outcome data of its own.
It is not valid to assume the SELECT cardiovascular benefit transfers to a compounded formulation. The molecule may be the same, but the evidence attaches to the studied product, not to every preparation containing semaglutide.
This is a recurring theme in GLP-1 evidence: trial results belong to the specific product and dose studied, and bridging them to compounded or altered formulations requires evidence that does not currently exist.
| Supports | Does not support |
|---|---|
| Approved semaglutide for CV risk reduction | Compounded semaglutide CV claims |
| Benefit in studied CVD population | Automatic benefit for everyone |
The bottom line
SELECT established that semaglutide 2.4mg reduces major cardiovascular events by about 20% in a high-risk population without diabetes, a landmark finding that reframed the drug as cardiovascular therapy, not only a weight-loss tool.
The result applies to the FDA-approved product in the studied population. It does not transfer to compounded semaglutide, which has no cardiovascular outcome evidence.
If cardiovascular risk reduction is a goal, that is a specific reason to discuss the approved product with your clinician.
Frequently asked questions
What did SELECT show?
Semaglutide 2.4mg reduced major adverse cardiovascular events by about 20% in adults with cardiovascular disease and overweight or obesity, without diabetes.
Does this apply to compounded semaglutide?
No. SELECT tested the FDA-approved product. Compounded semaglutide has no cardiovascular outcome evidence of its own.
Is the benefit only from weight loss?
No. The cardiovascular benefit appeared only partly explained by weight loss, suggesting effects beyond it.
Who benefits most?
The result is most applicable to adults resembling the trial population: established cardiovascular disease with overweight or obesity, without diabetes.
Sources
- FDA — human drug compounding and drug labels (Drugs@FDA).
- NEJM — STEP, SELECT, SURMOUNT and SURPASS trial publications.
- Official prescribing information and ClinicalTrials.gov registrations.
- Evidence status definitions: evidence policy.
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $49 to $279 a month across the 22 programmes we priced on October 15, 2026, with a median of $99. The spread is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $87 and Eden at $99; lower stickers come with a sale, a prepaid year or a membership. Half the programmes sit below $99 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Two programmes printed a semaglutide microdose price on October 15, 2026 (Shed from $149, Noom Med $179); NexLife's microdose semaglutide has cost the same as its standard plan since November 8, 2026 ($109 a month month-to-month). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Three questions to ask before acting on semaglutide
On October 15, 2026, compounded semaglutide ran $49 to $279 a month across the 22 programmes we priced.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
Standard-dose semaglutide spans $49 to $279 a month across the 22 programmes we priced on October 15, 2026, a spread of $230.
At the October 15, 2026 semaglutide median of $99 a month, medication alone runs $1,188 a year, $3,564 over three and $5,940 over five. At $279, the highest all-in rate we read, the same horizons are $3,348, $10,044 and $16,740.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What does compounded semaglutide normally cost?
$49 to $279 a month at the lowest all-in rate across the 22 programs we priced on October 15, 2026, with a median of $99. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed semaglutide cheaper?
Because it is less medicine. On October 15, 2026, Shed listed a semaglutide microdose from $149 a month and Noom Med at $179 after a $79 start. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What does compounded semaglutide cost per month in October 2026?
As of October 15, 2026, the 22 compounded semaglutide programs we could price on their own pages charge between $49 and $279 a month at their lowest all-in rate, with a median of $99, counting any required membership and the cheapest plan term each program prints. The low end is made of sale and "as low as" prices: WellMedr's fall sale and NextMeds both start at $49. Standing month-to-month rates with no membership start at $87 (Mondae) and $99 (Eden). Compounded semaglutide is not FDA-approved.